Sponsors (2)
The bill seeks to improve detection, care coordination, and research for uterine fibroids and related pain disparities—especially for underserved women—at the cost of new federal/state spending and with risks that uneven funding, implementation gaps, and capacity or privacy issues could limit who actually benefits.
Women with or at risk for uterine fibroids will likely receive earlier detection and treatment because the bill funds research, evidence-based detection strategies, and screening/imaging services.
Patients and clinicians will see better care coordination and more standardized, evidence-informed practices through funded patient navigation services and guidance for hospitals and providers.
Underserved and low‑income communities could gain improved access to screening, outreach, and treatment via grants, public awareness campaigns, and programs targeted by grantees.
Because the bill creates new grant programs without guaranteed appropriations in some sections, promised grants and programs may never be funded or implemented.
Taxpayers could face increased federal (and state) spending to support research, grants, screening services, reports, and program administration.
If funding is limited or uneven, access to expanded screening, navigation, and research will be patchy, leaving many women and low‑income communities without new services.
Based on analysis of 5 sections of legislative text.
Authorizes HHS to fund research and state grants to improve early detection, intervention, public education, and state research on uterine fibroids and related intrauterine conditions, with biennial reporting.
Introduced July 30, 2025 by Angela Deneece Alsobrooks · Last progress July 30, 2025
Creates federal research and state grant programs to improve early detection, intervention, public education, and access to care for people with uterine fibroids. Directs HHS to develop evidence-based detection strategies, fund state screening and patient navigation programs, support state research (including clinical trials) on pain-control disparities and intrauterine conditions, and post biennial reports to Congress and the public. Grants and research are authorized but no specific funding amounts, eligibility rules, or award deadlines are specified; reporting begins no later than two years after the first grants are awarded and continues every two years.